New England Research & Management’s Axsome Therapeutics AXSM Stock Holding History

New England Research & Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318K	Buy	+1,300	New	+$282K	0.12%	121

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

New England Research & Management's AXSM Position: Q2 2026 in Review

New England Research & Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,300 shares worth $318K. The stake represents 0.12% of the portfolio and ranks #121 among its holdings.

113 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

New England Research & Management held 1,300 shares of Axsome Therapeutics worth $318K as of Q2 2026.
Axsome Therapeutics was a new New England Research & Management position in Q2 2026.
Axsome Therapeutics made up 0.12% of New England Research & Management's portfolio in Q2 2026, its #121 holding.
113 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.